The study examined the efficacy and safety of almonertinib in combination with chemotherapy and almonertinib alone as a second-line treatment for NSCLC.
In this study, we tested the efficacy and safety of almonertinib in combination with chemotherapy versus almonertinib alone as second-line treatment in advanced non-small cell lung cancer (NSCLC) with a mutation in the Epidermal Growth Factor Receptor (EGFR) gene.
The study included clinical information on 68 patients with advanced NLD who were treated at Jiangsu Provincial People's Hospital and Nanjing Chest Hospital between April 2020 and December 2022. Of these, 30 patients received second-line treatment consisting of a combination of almonertinib and platinum-based chemotherapy, and 38 patients received almonertinib alone (control group). The researchers also compared long- and short-term outcomes and side effects between the two groups.
The median follow-up ended on December 31, 2022, and was 16.3 months.
A log-rank test comparing the study groups showed that the median progression-free survival (mPFS) in the study group was significantly higher than in the control group by 3.1 months (12.7 vs. 9.6 months; p = 0.01). A multivariate proportional hazards test of COX demonstrated a significant treatment benefit.
The researchers concluded that the combination of almonertinib and chemotherapy is superior to almonertinib alone as second-line therapy in advanced EGFR-mutated NSCLC.
Source:
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1248690/full
